A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study by Youle, Mike et al.
............................................................................................................................................
A Randomised Trial of Subcutaneous Intermittent
Interleukin-2 without Antiretroviral Therapy
in HIV-Infected Patients: The UK–Vanguard Study
Mike Youle
1, Sean Emery
2*, Martin Fisher
3, Mark Nelson
4, Lisa Fosdick
5, George Janossy
1, Clive Loveday
1,
Ann Sullivan
4, Christian Herzmann
1, Handan Wand
2, Richard T. Davey Jr.
6, Margaret A. Johnson
1,
Jorge A. Tavel
6, H. Clifford Lane
6*
1 Royal Free Centre for HIV Medicine, London, United Kingdom, 2 National Centre in HIV Epidemiology and Clinical Research, University of New South
Wales, Sydney, Australia, 3 Brighton Healthcare Trust, Brighton, United Kingdom, 4 Kobler Centre, London, United Kingdom, 5 Division of Biostatistics,
University of Minnesota, Minneapolis, United States of America, 6 National Institute of Allergy and Infectious Disease, National Institutes of Health,
Bethesda, Maryland, United States of America
Trial Registration: ClinicalTrials.gov:
NCT00000909
Funding: Funding for this study was
provided by the National Institute of
Allergy and Infectious Diseases,
National Institutes of Health, United
States Department of Health and
Human Services, Bethesda, Maryland,
United States of America. The
National Centre in HIV Epidemiology
andClinicalResearchisfundedbythe
Australian Government Department
of Health and Ageing and is affiliated
with the Faculty of Medicine at the
University of New South Wales.
ChironCorporationprovidedIL-2and
branched DNA assays for plasma HIV
RNA quantitation. Chiron
Corporation didnotcontribute tothe
study design, conduct, manuscript
preparation, or decision to submit for
publication.
Competing Interests: A patent for
immune enhancement through the
use of intermittent IL-2 therapy is
held by the United States
government citing HCL as an
inventor. HCL also receives research
support from Chiron Corporation in
the form of a Collaborative Research
and Development Agreement.
Citation: Youle M, Emery S, Fisher M,
Nelson M, Fosdick L, et al. (2006) A
randomised trial of subcutaneous
intermittent interleukin-2 without
antiretroviral therapy in HIV-infected
patients: The UK-Vanguard study.
PLoS Clin Trials 1(1): e3. DOI: 10.
1371/journal.pctr.0010003
Received: February 15, 2006
Accepted: March 10, 2006
Published: May 19, 2006
DOI: 10.1371/journal.pctr.0010003
This is an open-access article
distributed under the terms of the
Creative Commons Public Domain
declaration, which stipulates that,
once placed in the public domain,
this work may be freely reproduced,
distributed, transmitted, modified,
built upon, or otherwise used by
anyone for any lawful purpose.
Abbreviations: AUC, area under
curve; CI, confidence interval; IL-2,
interleukin-2; MIU, million
international units
* To whom correspondence should
be addressed. E-mail: semery@
nchecr.unsw.edu.au (SE), clane@
niaid.nih.gov (HCL)
ABSTRACT
Objective: The objective of the trial was to evaluate in a pilot setting the safety and efficacy of
interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a
treatment for HIV infection.
Design and Setting: This was a multicentre randomised three-arm trial conducted between
September 1998 and March 2001 at three clinical centres in the United Kingdom.
Participants: Participants were 36 antiretroviral treatment naı ¨ve HIV-1-infected patients with
baseline CD4 T lymphocyte counts of at least 350 cells/mm
3.
Interventions: Participants were randomly assigned to receive IL-2 at 15 million international
units (MIU) per day (12 participants) or 9 MIU/day (12 participants) or no treatment (12
participants). IL-2 was administered by twice-daily subcutaneous injections for five consecutive
days every 8 wk.
Outcome Measures: Primary outcome was the change from baseline CD4 T lymphocyte
count at 24 wk. Safety and plasma HIV RNA levels were also monitored every 4 wk through 24
wk. The two IL-2 dose groups were combined for the primary analysis.
Results: Area under curve (AUC) for change in the mean CD4 T lymphocyte count through 24
wk was 129 cells/mm
3 for those assigned IL-2 (both dose groups combined) and 13 cells/mm
3
for control participants (95% CI for difference, 51.3–181.2 cells/mm
3; p¼0.0009). Compared to
the control group, significant increases in CD4 cell count were observed for both IL-2 dose
groups: 104.2/mm
3 (p ¼ 0.008) and 128.4 cells/mm
3 (p ¼ 0.002) for the 4.5 and 7.5 MIU dose
groups, respectively. There were no significant differences between the IL-2 (0.13 log10 copies/
ml) and control (0.09 log10 copies/ml) groups for AUC of change in plasma HIV RNA over the
24-wk period of follow-up (95% CI for difference,  0.17 to 0.26; p ¼ 0.70). Grade 4 and dose-
limiting side effects were in keeping with those previously reported for IL-2 therapy.
Conclusions: In participants with HIV infection and baseline CD4 T lymphocyte counts of at
least 350 cells/mm
3, intermittent subcutaneous IL-2 without concomitant antiretroviral therapy
was well tolerated and produced significant increases in CD4 T lymphocyte counts and did not
adversely affect plasma HIV RNA levels.
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PLoS CLINICAL TRIALSINTRODUCTION
The development of combination antiretroviral therapy for
the treatment of HIV infection has produced a marked
decline in AIDS and death, but enthusiasm for these treat-
ments in patients with early stages of HIV infection has been
tempered by long-term toxicity, such as lipodystrophy and
lactic acidosis, difﬁculties with maintaining rigorous com-
pliance, and the evolution of drug resistant HIV [1–5]. The
use of these treatments for prolonged periods may not be
achievable, and treatment guidelines continue to change [6–
8]. For these reasons, the development of alternate therapies
or treatment strategies continues. One such strategy is the
administration of intermittent interleukin-2 (IL-2) to aug-
ment or preserve immune function [9–11].
IL-2 is a cytokine that in vivo is secreted by activated T
lymphocytes. IL-2 regulates the proliferation, differentiation,
and survival of lymphocytes, including CD4 T cells [12].
Increases in CD4 T lymphocyte count arising from the use of
intermittent IL-2 in combination with antiretroviral therapy
have been demonstrated consistently in a number of
randomised clinical trials [13–21]. The use of recombinant
IL-2 has been associated with transient rises of plasma HIV
RNA levels in some patients [13–14]. However, no signiﬁcant
persistent increase in HIV RNA has been observed in IL-2
recipients when compared to controls treated with combi-
nation antiretroviral therapy [13–21]. In fact, a pooled
analysis of long-term follow-up data from the ﬁrst three
randomised controlled trials of intermittent IL-2 suggested
that IL-2 in combination with antiretroviral therapy pro-
duced larger decreases in viral load than antiretroviral
therapy alone [22]. One randomised study similarly found
that IL-2 in combination with antiretroviral therapy pro-
duced larger decreases in viral load than antiretroviral
therapy alone [18], although these ﬁndings were not observed
in other randomised studies of short duration [13–17,19–21].
The purpose of this randomised controlled pilot trial was
to determine whether intermittent IL-2 therapy administered
without concomitant antiretroviral therapy safely increased
CD4 T lymphocyte counts. Ultimately, if this strategy were to
be successful, it might lead to a delay in the time at which
chronic antiretroviral therapy would need to be initiated.
Further trials would be required from which to draw any
deﬁnitive conclusions.
METHODS
Participants
Patients 18 y or older who had HIV-1 infection and CD4 T
lymphocyte counts of at least 350 cells/mm
3 at screening were
eligible for enrollment if they had never received IL-2 or
antiretroviral therapy. Additional eligibility criteria required
that participants had no history of AIDS-deﬁning illness and
had received no corticosteroids, cytotoxic chemotherapy, or
experimental cytotoxic therapy in the preceding 4 wk.
Participants were required to have blood cell proﬁles and
serum chemistry values within acceptable ranges. The study
was approved by the National Institute of Allergy and
Infectious Diseases’ institutional review board and also by
each site’s research ethics committee. All participants
provided written informed consent. An independent data
and safety monitoring board reviewed safety and efﬁcacy data
on one occasion during the conduct of the trial. Patients were
recruited and followed, and one of three participants’ sites
provided primary healthcare.
Interventions
Participants were randomly assigned in equal proportions to
intermittent subcutaneous injections of IL-2 at two dosage
levels (4.5 million international units [MIU] or 7.5 MIU twice
daily for ﬁve consecutive days every 8 wk) or no treatment.
The study was not placebo controlled, as the constitutional
side effects of IL-2 make blinding impractical. IL-2 (aldesleu-
kin [Proleukin], Chiron, Emeryville, California, United States)
was administered either in a hospital clinic or through an
outpatient department. Dose modiﬁcations in decrements of
1.5 MIU were allowed for the management of clinical or
laboratory toxicities.
Objectives
Our primary hypothesis was that intermittent cycles of IL-2
would result in signiﬁcant increases in CD4 T lymphocyte
counts relative to no therapy. Our secondary hypotheses were
that there would be no signiﬁcant increases in plasma HIV
RNA between treatment groups and that IL-2 cycles would be
safe and well tolerated, in keeping with the experience of
earlier studies.
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Editorial Commentary
Background: There is very good trial evidence that combinations of
antiretroviral drugs improve the prognosis of people with HIV infection.
However, these drugs can have major side effects, and HIV can become
resistant to them. The development of alternative treatments might
allow antiretroviral use to be delayed in some people, thereby reducing
toxicity and the emergence of resistant strains of HIV.
What this trial shows: The researchers studied 36 adult patients in the
United Kingdom who were infected with HIV and who had not
previously been prescribed antiretrovirals. Participants in the trial were
given either one of two different dosage levels of IL-2 (a chemical
messenger normally produced in the body by particular immune cells)
by injection under the skin or no treatment at all. Patients given IL-2 at
either dosage experienced an increase in levels of CD4 T lymphocytes,
the type of immune cell depleted by HIV infection, as compared to
patients receiving no treatment. The viral load in patients receiving IL-2
did not differ from that of patients in the control arm.
Strengths and limitations: The rationale for this trial—to delay
administration of antiretroviral drugs—is sound, as is the experimental
design. The results are limited, however, by the short follow-up of
patients in the trial and by the lack of clinical endpoints (such as disease
progression), so it is not possible to tell whether patients in the trial
benefited directly from the IL-2 treatment.
Contribution to the evidence: The clinical effectiveness and safety of IL-
2 together with antiretrovirals as a treatment for HIV infection is
currently being evaluated in other, large-scale trials. To date, no other
study has assessed the outcomes arising from administration of IL-2
alone. Data from the current trial will be useful in planning further
research to examine whether IL-2 might help delay antiretrovirals in HIV-
positive people.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Outcomes
Over the 24-wk study period, participants were evaluated
monthly, with additional visits of the IL-2-treated partic-
ipants at day 5 of each cycle. Clinical assessments involved
physical examination, complete blood counts with differ-
entials and platelet counts, serum chemistry proﬁles, T
lymphocyte subset enumeration, and plasma HIV RNA
quantitation.
Absolute CD4 and CD8 T lymphocyte counts were
determined from 100 ll of fresh EDTA blood, by direct
immunoﬂuorescence using the Ortho-Trio method [23,24].
Particle-associated plasma HIV RNA concentrations were
determined using a branch-chain DNA assay (Chiron) with a
lower limit of detection at 50 copies/ml plasma [25,26]. Flow
cytometry and HIV quantitation were performed at a single
laboratory throughout the study.
A treatment failure was prospectively deﬁned as any
patient who experienced either at least a 1-log increase in
plasma HIV RNA on two consecutive occasions more than 29
d apart in the absence of an intercurrent illness, a greater
than 25% reduction from the baseline CD4 T lymphocyte
count on two occasions more than 29 d apart in the absence
of intercurrent illness, and/or initiation of antiretroviral
therapy for any reason.
Sample Size
Sample size was speciﬁed as 36 participants in order to
provide 80% power to detect a difference between both IL-2
dose groups combined and the control group of 150 CD4 T
lymphocytes/mm
3 at a two-sided signiﬁcance level of 5%.
With this sample size, power was also 80% to detect a
difference of 0.7-log copies of HIV RNA per cubic millimeter
between treatment groups. These estimates were considered
conservative because they did not consider the averaging of
multiple follow-up measurements of CD4 and HIV RNA that
were to be used for the primary analysis.
Randomisation
Randomisation was performed through using a central
randomisation ofﬁce located at the University of Minnesota.
Computer-generated randomisation lists were generated at
this ofﬁce using a blocking factor of 6. Allocation of patients
was by facsimile request from participant sites to the
University of Minnesota randomisation ofﬁce.
Statistical Methods
The primary end points of the study were area under the
curve (AUC) for CD4 T lymphocyte count change from
baseline and AUC for plasma HIV RNA change from baseline
over the 24 wk of the study. The AUC estimates were
standardised for the timing of the last measurement for each
person [27]. Secondary end points included the comparative
frequency of protocol-deﬁned treatment failure, changes in
percentage of CD4 T lymphocytes, the number and percent-
age of CD8 T lymphocytes, the CD4/CD8 T lymphocyte ratio,
and safety data. Plasma HIV RNA data were log10 trans-
formed prior to analyses.
Baseline was the average of three measurements made
within 30 d of randomisation. Levels at 24 wk were the
average of three measurements within 2 wk of one another.
Follow-up levels at other weeks were based on a single
reading.
Data for patients assigned IL-2 were analysed on an
intention-to-treat basis; i.e., all follow-up measurements were
included even if the patient was not taking IL-2. Data from
one participant in the control group who initiated antiret-
roviral therapy are only included up to the time antiretroviral
therapy commenced. As stated in the protocol, for the
primary analyses, the combined data from the two IL-2 dose
groups were compared with control participants. Pairwise
comparisons between each of the randomly assigned treat-
ment arms and the control group and with one another were
also carried out. In addition to AUC analyses, longitudinal
regression methods that take into account correlations within
and between participants were used to estimate the average
difference between treatment groups (IL-2 and control) over
follow-up and to estimate the differences in CD4 T
lymphocytes and plasma HIV RNA at each follow-up time-
point [28]. These analyses were carried out using the PROC
Mixed procedure of the SAS Institute (Cary, North Carolina,
United States). Other analyses were also carried out with the
use of the SAS Version 8 software. All statistical tests were
two-sided, with a p-value of ,0.05, indicating statistical
signiﬁcance.
RESULTS
Patient Disposition, Recruitment, and Baseline
Characteristics
A total of 45 patients were screened for participation.
Disposition of the cohort over the entire period of follow-
up is shown in Figure 1. Prior AIDS diagnoses (one
participant) and low CD4 cell counts (eight participants)
accounted for all ineligible screens. The remaining 36
participants were enrolled between September 1998 and
August 1999. Of these, 12 were randomly assigned to each of
the IL-2 treatment groups (giving a total of 24 IL-2 recipients)
and 12 to the control group. No patients were lost to follow-
up for the purposes of clinical assessment. However, ﬁve
control patients and seven IL-2 recipients did not contribute
laboratory data to the week 24 assessments. The baseline
characteristics of the three groups were similar (Table 1).
Exposure to IL-2
The exposure of participants randomised to receive IL-2 is
summarised in Table 2. During the 24-wk study period, most
participants in either treatment group completed three
treatments with IL-2. However, participants randomised to
receive the 7.5 MIU dose reduced more frequently than those
randomised to 4.5 MIU, and at week 24 the average unit dose
of IL-2 was only 5.8 MIU. This is in contrast with the 4.2 MIU
average unit dose for patients randomised to receive IL-2 at
4.5 MIU/dose.
Immunologic Measures
CD4 T lymphocyte counts over follow-up for each treatment
group, based on longitudinal regression, are illustrated in
Figure 2. At each follow-up visit except the 8-wk visit, CD4 T
lymphocyte increases from baseline were signiﬁcantly greater
for those assigned IL-2 compared to control. At 24 wk, this
difference was 132 cells/mm
3 (p¼0.02). AUC for change in the
mean CD4 T lymphocyte count through 24 wk was 129 cells/
mm
3 for those assigned IL-2 (both dose groups combined)
and 13 cells/mm
3 for control participants (95% CI for
difference, 51.3–181.2 cells/mm
3; p ¼ 0.0009). As shown in
Table 3, the AUC for change in CD4 T lymphocyte count
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(þ129.4 cells/mm
3) compared to control (þ13.1 cells/mm
3)
(difference, 116.2 cells/mm
3; 95% CI for difference, 51.3–
181.2 cells/mm
3). Longitudinal regression analysis yielded a
similar difference between treatment groups (132.3 cells/
mm
3; p¼0.0001). Statistically signiﬁcant differences were also
observed for the pairwise comparisons of each IL-2 dose with
control (p¼0.002 for 7.5 MIU versus control; p¼0.008 for 4.5
MIU versus control), but not for the comparison of IL-2 doses
4.5 MIU versus 7.5 MIU (p ¼ 0.57). The numbers of CD8 T
lymphocytes in each treatment group remained stable
throughout the period of observation in each treatment
group (unpublished data).
Virologic Measures
The AUC for change in plasma HIV RNA from baseline was
similar for those assigned IL-2 (0.13 log10 copies/ml) and
control (0.09 log10 copies/ml) (95% CI for difference, 0.17 to
0.26; p ¼ 0.70) (Table 3). Similarly, there were no signiﬁcant
differences between treatment groups for mean changes in
log10 HIV RNA at any timepoint in this parameter. Analyses
based on longitudinal regression produced results similar to
AUC (average difference, 0.11; p ¼ 0.32).
Evaluation of plasma HIV RNA at the end of each 5-d cycle
of IL-2 administration revealed a transient increase of at least
0.5 log10 HIV RNA in 32% of patients in cycle 1, 40% of
patients in cycle 2, and 37% of patients in cycle 3. These
increases ranged from 0.5 to 1.6 log10 HIV RNA. There were
no statistically signiﬁcant differences between the 4.5 MIU
and 7.5 MIU dose groups (unpublished data).
Toxicities and Safety Data
Following randomisation, one participant in each IL-2 dose
group declined IL-2 therapy before receiving their ﬁrst cycle,
but their data have been included in the 24-wk analyses. One
additional participant in the 4.5 MIU dose group permanently
discontinued IL-2 after completing one cycle, citing personal
reasons. Two additional participants in the 7.5 MIU dose
group discontinued therapy, citing toxicity (one participant
after completing two cycles), and multiple reasons, including
toxicity and CD4 T lymphocyte count decrease (one partic-
ipant after completing three cycles), as the reasons for
Figure 1. Flow Diagram of Study Design and Patient Disposition
DOI: 10.1371/journal.pctr.0010003.g001
.......................................................................................................................................................................................
Table 1. Demography and Baseline Characteristics
Characteristic Treatment Group
Control 4.5 MIU IL-2 7.5 MIU IL-2 Combined IL-2
n 12 12 12 24
Mean age (y) 38.0 31.8 36.9 34.4
Mean weight (kg) 71.4 71.7 74.7 73.2
Number female 0 0 1 1
Percentage homosexual 100 91.7 83.3 87.5
Percentage antiretroviral naı ¨ve 100 100 100 100
Median CD4 cell count (cells/mm
3) 477 423 388 393
Median nadir CD4 cell count (cells/mm
3) 447 396 352 372
Median plasma HIV RNA (log10 copies/ml) 4.1 4.2 4.4 4.3
DOI: 10.1371/journal.pctr.0010003.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.plosclinicaltrials.org May | 2006 | e3 0004
IL-2 Therapy without Antiretroviral Drugs in HIVdiscontinuation. No new side effects were encountered. The
most numerous dose-limiting events were constitutional signs
and symptoms, including fever and nausea. Five grade 4 events
were reported during the trial as follows: diarrhea (4.5 MIU),
pancreatitis (7.5 MIU), abdominal pain with hyperamylasemia
(7.5 MIU), elevated alanine aminotransferase (4.5 MIU), and
abdominal cramps with diarrhea (control). There were no
deaths during follow-up.
Protocol-Defined Treatment Failures and Clinical
Disease Progression
On the basis of the protocol deﬁnition, three patients
experienced treatment failure during the 24-wk follow-up
period: two control participants (one commenced antiretro-
viral therapy at week 16 after being diagnosed with non-
visceral Kaposi’s sarcoma and one had a decreased CD4
count); and one participant assigned 7.5 MIU IL-2 (who
commenced antiretroviral therapy at week 24 after being
diagnosed with visceral Kaposi’s sarcoma).
DISCUSSION
Overall Evidence
Studies of intermittent administration of IL-2 in combination
with antiretroviral therapy have demonstrated signiﬁcant and
sustained increases in CD4
þ T cell count resulting from a
preferentialincreaseinCD4
þT cell survivalanddecreased cell
turnover in the setting of decreased immune activation
[29,30]. In this pilot study, CD4 T lymphocyte counts increased
signiﬁcantly in the IL-2 monotherapy arm, compared with the
Figure 2. CD4
þ Cell Count with 95% CI and Number of Patients with CD4 Cell Count Used in the Analysis
DOI: 10.1371/journal.pctr.0010003.g002
.......................................................................................................................................................................................
Table 2. Exposure of Participants to IL-2, Shown by Number of Participants Commencing Each Cycle and Average Unit Dose in Each
Cycle by Treatment Group
Cycle Number Treatment Group
4.5 MIU 7.5 MIU
Number Starting Cycle Average Unit Dose (MIU) Number Starting Cycle Average Unit Dose (MIU)
1 11 4.5 11 7.3
2 9 4.4 11 6.6
3 9 4.2 10 5.8
DOI: 10.1371/journal.pctr.0010003.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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not associated with sustained increases in HIV RNA load.
Measurements of plasma HIV RNA in IL-2 recipients at the
end of each 5-d cycle of IL-2 indicated that transient bursts of
viremia were consistent with those observed in previous trials
in which patients were treated with what would currently be
regarded as suboptimal regimens of antiretroviral therapy [3–
15]. Despite these transient bursts, there were no long-term
changes in viral load.
The clinical signiﬁcance of the increase in CD4 T
lymphocytes that are produced under the inﬂuence of IL-2
therapy is uncertain and has led to the initiation of two large
clinical endpoint studies (SILCAAT and ESPRIT [31]) to
assess the clinical consequences of IL-2 in combination with
antiretroviral therapy. SILCAAT and ESPRIT are sister
studies, the former assessing HIV-infected participants with
between 50 and 300 cells/mm
3 and HIV RNA levels of
,10,000 copies/ml, and the latter in participants with  300
cells/mm
3 and no restriction on viral load.
Prior to ESPRIT, four Vanguard studies were conducted to
address methodological and operational issues for studies of
IL-2 therapy [19–21]. The pilot study reported here, the UK–
Vanguard, was initiated to examine IL-2 treatment without
antiretroviral medication. A striking feature of the data from
this study relative to that from the others is a relatively
blunted CD4 T lymphocyte count response. The mean
increase in CD4 T lymphocyte count observed at 24 wk
compared to control was 132 cells/mm
3, considerably less
than that observed in the other three Vanguard studies (an
average increase of 328, 459, and 347 from baseline above
those achieved by the control groups [19–21].
Interpretation
The reasons for the clearly blunted response in the current
trial are not known, but one possible explanation is that, in
patients with ongoing uncontrolled virus replication, a larger
proportion of the newly emerging CD4 T lymphocytes are
eliminated. It is less likely that these differences in CD4 T
lymphocyte count increases are due to the doses of IL-2
actually administered. In the other Vanguard studies, the
average total doses of IL-2 given over the ﬁrst three cycles to
the 7.5 MIU arm (maximum of 225 MIU) were about 198–225
MIU, while in this study the average total dose of IL-2 given
over the ﬁrst three cycles to the 7.5 MIU arm was only
minimally lower (192 MIU).
In this protocol we did not assess T-cell function. Neither
did we choose to examine distinct subsets of CD4
þ T
lymphocytes that are believed to be of signiﬁcance in the
immunopathogenesis of HIV disease. In many other trials of
subcutaneous IL-2, a consistent observation has been that the
functionality and/or immunophenotype of T cells present
prior to IL-2 administration remains following IL-2 treat-
ment, although in some settings there appears to be a
preferential expansion of naı ¨ve CD4
þ T lymphocytes [29–
30,32]. A role for IL-2 in restoring or perhaps inducing anti-
HIV-speciﬁc immune responses has not been part of the
hypothesis behind the therapeutic evaluation of IL-2 in our
hands. In the current study we were encouraged by the
absence of any within- or between-treatment group differ-
ences in HIV RNA plasma load. We infer from this
observation that any active anti-HIV-speciﬁc immune re-
sponses were unaffected by the administration of IL-2 in this
study.
Generalisability
As observed in other trials, this study demonstrates that IL-2
is well tolerated at doses that produce signiﬁcant increases in
CD4 T lymphocyte counts. Toxicities occurred only during
the intermittent cycles of IL-2, were mostly mild to moderate
in severity, and were managed with a comprehensive
approach that included dose modiﬁcation and the use of
medications to control signs and symptoms. Grade 4 events
occurred once in four IL-2 recipients and once in a control
patient. Across the 66 treatment cycles initiated in this trial,
this number of grade 4 events indicates a prevalence of
approximately 6% for events of this severity. No novel
toxicities were observed.
While the sample size for this study was only 36 and not all
patients provided data at the ﬁnal timepoint for the primary
measure of interest, the lower limit of the 95% CI for CD4 T
lymphocyte (51 cells/mm
3) and the upper limit for plasma
HIV RNA difference from control (0.32 copies/ml) indicate
that at least modest CD4 T lymphocyte increases are possible
without adversely affecting viral load. Thus, these ﬁndings are
sufﬁciently encouraging to plan other studies of intermittent
monotherapy with IL-2 to study its potential for increasing or
maintaining CD4 T cell counts and prolonging the time to
initiation of antiretroviral therapy.
In summary, this pilot study demonstrated that intermit-
tent IL-2 therapy alone can be used to safely and signiﬁcantly
.......................................................................................................................................................................................
Table 3. AUC for CD4 T Lymphocyte Count and HIV RNA Change from Baseline
Dose Group and Treatment Group AUC CD4
þ (cells/mm
3) p-Value AUC HIV RNA (log10) p-Value
Overall
IL2 129.4 0.001 0.13 0.70
Control 13.1 0.09
4.5 MIU
IL2 117.3 0.008 0.22 0.21
Control 13.1 0.09
7.5 MIU
IL2 141.5 0.002 0.03 0.66
Control 13.1 0.09
IL2
4.5 MIU 117.3 0.57 0.22 0.19
7.5 MIU 141.5 0.03
DOI: 10.1371/journal.pctr.0010003.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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improve CD4 T lymphocyte counts in HIV-infected individ-
uals with baseline CD4 T lymphocyte counts .350 cells/mm
3
with no detrimental effect on HIV replication as measured by
plasma HIV RNA load. Ongoing studies are addressing the
clinical consequences of these CD4 T lymphocyte rises and
the signiﬁcance of these ﬁndings in terms of current models
used to describe the interplay between virus and host in the
setting of HIV infection.
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010003.sd001 (54 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010003.sd002 (337 KB DOC).
ACKNOWLEDGMENTS
We thank the patients for their support of this trial. The data and
safety monitoring board was comprised of Dr. Anne McLaren,
Professor Peter Armitage, Professor Val Beral, Professor Harold
Lambert, and Professor Maxime Seligmann.
Author Contributions
MY, SE, GJ, CL, RTD, and HCL conceived and designed the
experiments. MY, MF, MN, GJ, CL, AS, RTD, MAJ, JAT, CH and
HCL performed the experiments. MY, MF, MN, AS, and MAJ enrolled
the patients. MY, SE, LF, CL, CH, HW, JAT, and HCL analysed the
data. MF was the principal investigator at one of the three sites and
was involved in the writing of the manuscript. GJ’s group contributed
to the immunological testing of the patients throughout the trial.
CL’s laboratory collected and saved samples, carried out the
molecular assays described in this study, and performed all
appropriate quality control experiments to assure quality of the
results. AS ran the study from a clinical point of view at one of the
three sites (including administering IL-2 and obtaining samples and
data), was involved in laboratory processing and analysis of blood
samples, and contributed to the review of the ﬁnal manuscript draft.
RTD provided scientiﬁc consultation to the ongoing data analysis and
manuscript draft. All authors contributed to the writing of the paper.
REFERENCES
1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998)
Declining morbidity and mortality among patients with advanced human
immunodeﬁciency virus infection: HIV Outpatient Study Investigators. N
Engl J Med 338: 853–860.
2. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet
356: 1423–1430.
3. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy,
lactic acidaemia and liver dysfunction associated with HIV nucleoside
analogue therapy: Contribution to protease inhibitor-related lipodys-
trophy syndrome. AIDS 14: F25–F32.
4. Crespo-Fierro M (1997) Compliance/adherence and care management in
HIV disease. J Assoc Nurses AIDS Care 8: 43–54.
5. Pillay D, Taylor S, Richman DD (2000) Incidence and impact of resistance
against approved antiretroviral drugs. Rev Med Virol 10: 231–253.
6. PanelonClinicalPracticesforTreatmentofHIVInfection(2004)Guidelines
for the use of antiretroviral agents in HIV-infected adults and adolescents.
Rockville (Maryland): US Department of Health and Human Services.
Available: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
Accessed 24 March 2006.
7. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schecter M, et al. (2004)
Treatment for adult HIV infection: 2004 recommendations of the
International AIDS Society–USA panel. JAMA 292: 251–265.
8. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, et al. (2003) The
British HIV Association HIV treatment guidelines. Available http://www.
bhiva.org/pdf/2003/guides/BHIVA_2003_Guidelines.pdf. Accessed 24
March 2006.
9. Emery S, Lane HC (1996) Immune-based therapies in HIV infection: Recent
developments. AIDS 10 (Suppl A): S159–S163.
10. Stein DS, Timpone JG, Gradon JD, Kagan JM, Schnittman SM (1993)
Immune-based therapeutics: Scientiﬁc rationale and the promising
approaches to the treatment of the human immunodeﬁciency virus-
infected individual. Clin Infect Dis 17: 749–771.
11. Lederman MM (1995) Host-directed and immune-based therapies for
human immunodeﬁciency virus infection. Ann Intern Med 122: 218–222.
12. Smith KA (1988) Interleukin-2: Inception, impact and implications. Science
240: 1169–1176.
13. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, et al. (1996)
Controlled trial of interleukin-2 infusions in patients infected with the
human immunodeﬁciency virus. N Engl J Med 335: 1350–1356.
14. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, et al. (1997)
Subcutaneous administration of interleukin-2 in human immunodeﬁciency
virus type-1-infected persons. J Infect Dis 175: 781–789.
15. Carr A, Emery S, Lloyd A, Hoy J, Garsia R, et al. (1998) Outpatient
continuous intravenous interleukin-2 or subcutaneous, polyethylene
glycol-modiﬁed interleukin-2 in human immunodeﬁciency virus-infected
patients: A randomized, controlled, multicenter study. J Infect Dis 178:
992–999.
16. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, et al. (1999) A
randomized trial of high- versus low-dose subcutaneous interleukin-2
outpatient therapy for early human immunodeﬁciency virus type 1
infection. J Infect Dis 179: 849–858.
1 7 . L e v yY ,C a p i t a n tC ,H o u h o uS ,C a r r i e r eI ,V i a r dJ P ,e ta l .( 1 9 9 9 )
Comparison of subcutaneous and intravenous interleukin-2 in asympto-
matic HIV-1 infection: A randomized controlled trial. Lancet 353: 1923–
1929.
18. Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, et al. (2000)
Immunologic and virologic effects of subcutaneous interleukin 2 in
combination with antiretroviral therapy: A randomized controlled trial.
JAMA 284: 183–189.
19. Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, et al. (2000) A
randomized, controlled, phase II trial comparing escalating doses of
subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone
in human immunodeﬁciency virus-infected patients with CD4 cell counts
.350/mm
3. J Infect Dis 181: 1614–1621.
20. Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, et al.
(2000) A randomized, controlled 24 week study of intermittent subcuta-
neous interleukin-2 (IL-2) in HIV-1 infected patients in Thailand. AIDS 14:
2509–2513.
21. Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, et al. (2002)
Randomized, open-label study of the impact of two doses of subcutaneous
recombinant interleukin-2 on viral burden in patients with HIV-1 infection
and CD4þcell count  300/mm
3: CPCRA 059. J Acquir Immune Deﬁc Syndr
29: 221–231.
22. Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, et al. (2000)
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy
in adult human immunodeﬁciency virus type 1 disease. J Infect Dis 182:
428–434.
23. Connelly MC, Knight M, Giorgi JV, Kagan J, Landay AL, et al. (1995)
Standardization of absolute CD4 lymphocyte counts across laboratories: An
evaluation of the Ortho CytoronAbsolute ﬂow cytometry system on normal
donors. Cytometry 22: 200–210.
24. Mercolino TJ, Connelly MC, Meyer EJ, Knight MD, Parker JW, et al. (1995)
Immunologic differentiation of absolute lymphocyte count with an
integrated ﬂow cytometric system: A new concept for absolute T cell
subset determinations. Cytometry 22: 48–59.
25. Urdea MS, Wilber JC, Yeghiazarian T, Todd JA, Kern DG, et al. (1993)
Direct and quantitative detection of HIV-1 RNA in human plasma with a
branched DNA signal ampliﬁcation assay. AIDS 7: S11–S14.
26. Dewar RL, Highbarger HC, Sarmiento MD, Todd JA, Vasudevachari MB, et
al. (1994) Application of branched DNA signal ampliﬁcation to monitor
human immunodeﬁciency virus type 1 burden in human plasma. J Infect
Dis 170: 1172–1179.
27. Matthews JNS, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial
measurements in medical research. BMJ 300: 230–235.
28. Verbeke G, Molenberghs G (2001) Linear mixed models for longitudinal
data. New York: Springer Verlag. 608 p.
29. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, et al. (2005)
Induction of prolonged survival of CD4
þT lymphocytes by intermittent IL-
2 therapy in HIV-infected patients. J Clin Invest 115: 2139–2148.
30. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, et al.
(2005) In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in
IL-2-treated HIV-infected patients. J Clin Invest 115: 1839–1847.
31. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, et al. (2002) The
evaluation of subcutaneous proleukin (interleukin-2) in a randomized
international trial: Rationale, design, and methods of ESPRIT. Control Clin
Trials 23: 198–220.
32. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, et al.
(2004) IL-2-induced CD4
þ T cell expansion in HIV-infected patients is
associated with long-term decreases in T cell proliferation. Blood 104: 775–
780.
www.plosclinicaltrials.org May | 2006 | e3 0007
IL-2 Therapy without Antiretroviral Drugs in HIV